EADV Congress 2026: key results and trends

Regarding efficacy maintenance, among patients in the MG-K10 treatment group who achieved EASI-75 or IGA 0/1 with a ≥2-point reduction from baseline at Week 16, 98.9% maintained EASI-75 response and 92.6% maintained IGA response at Week 52.

Same trend also was found in PASI 100 response rates in gumokimab groups with 48.0% (150mg group) and 52.0% (300mg group) at week 12; and 68.9% (150mg group) and 74.8% (300mg group) at week 52.

Over a 12-week period Netakimab showed a favorable safety profile: 34.9% (29/83) of patients in the Netakimab group reported AEs (vs 40.0% in the Placebo group, and 45.9% - in the Adalimumab group).

Serious adverse events (SAEs) were reported in 2.5% (manfidokimab) and 2.8% (placebo) of patients, respectively, with the majority considered unrelated to the treatment.

During the 16-week treatment period, treatment-emergent adverse event (TEAE) occurred in 66.1% (228/345) of patients in the SSGJ-611 group and 65.5% (114/174) in the placebo group.

Disease control was also evident with the mean reduction in affected BSA from baseline (15.1%) to Week 8 (2.5%) being maintained at Week 24 (2.5%) with as-needed application of ruxolitinib cream.

A higher IGA 0/1 response was also observed in the Telikibart group (33.1% vs. 6.6%; difference, 26.5% [95% CI, 19.86-33.15]; P <0.0001).

During the main study, adverse events (AEs) were reported in 95.2%, 93.2%, and 76.4% of participants in the gecacitinib 75 mg, gecacitinib 100 mg, and placebo groups, respectively.

Adverse events reported in 42.5% vs 37.6% of patients on remibrutinib versus those on placebo, however, with longer median exposure to remibrutinib (24.0 weeks) than placebo (15.6 weeks).

From baseline to Week 16, the GUS-treated group achieved clinically important improvements in mean PsAID-12 score (least-squares mean change, −4.1 vs 0.2 with placebo; nominal p<0.001) and a mean score (2.9) below the PASS threshold.

Response rates continued to improve with continuous tralokinumab treatment up to Week 32 in the open-label period, with clinically meaningful improvements in DLQI and HEIS observed in 89.6% (n/N: 112/125) and 83.2% (99/119) of patients, respectively.

At Week 8, statistically significantly more tapinarof-treated than vehicle-treated patients achieved a vIGA-ADTM response (45.9% vs 15.9%, P<0.0001), based on MI‑estimand analyses, defined as vIGA-ADTM score of 0 or 1 and ≥2 grade improvement from baseline.